^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SJP1604

    i
    Other names: SJP1604, SJP 1604, APTA-16
    Associations

    News

    Trials
    Company:
    AptaBio, Samjin Pharma
    Drug class:
    Nucleolin inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost5years
    [VIRTUAL] In vivo PoC study and design for Phase I clinical study of SJP1604, a nucleolin-targeted therapeutic agent to treat entire population of relapsed/refractory acute myeloid leukemia patients (AACR 2021)
    Therefore, our results mentioned above are very noteworthy finding showing the high potential of SJP1604 to be further developed as the first innovative targeted therapy to treat entire population of R/R AML patients. Herein, we show a phase I clinical trial design of SJP1604 to perform an open-label, first-in-human, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity in patients with R/R AML.
    P1 data • Preclinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • NCL (Nucleolin)
    |
    SJP1604